Lineage Logistics Announces Appointment of New Chief Financial Officer
4.5.2023 15:00:00 EEST | Business Wire | Press release
Lineage Logistics (“Lineage” or the “Company”), one of the leading temperature-controlled industrial REIT and logistics solutions providers worldwide, today announced the appointment of Rob Crisci as Chief Financial Officer (“CFO”). Crisci brings more than 25 years of financial leadership experience in the industrial and technology sectors. He will report directly to Lineage’s President & Chief Executive Officer (“CEO”), Greg Lehmkuhl.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230504005022/en/
Lineage Logistics today announced the appointment of Rob Crisci as Chief Financial Officer. Mr. Crisci brings more than 25 years of financial leadership experience in the industrial and technology sectors to Lineage as the company continues its next phase of growth and expansion. (Photo: Business Wire)
Crisci joins Lineage from Roper Technologies (NYSE: ROP), a constituent of the S&P 500 and Fortune 500 that operates 27 independent businesses across multiple end markets, where he most recently served as the company’s Executive Vice President and Chief Financial Officer. In that role, he oversaw the multi-billion-dollar business’s global financial operation and played a central role in its transformation from a cyclical industrial company to one focused primarily on software, helping to increase recurring revenue, operating margins and organic growth. As a deeply experienced M&A professional, he successfully deployed over $20 billion in capital and led key acquisitions for Roper as it underwent its portfolio transformation. Prior to serving as CFO, he spent four years as Vice President of Finance and Investor Relations, enhancing the company’s relationships with banks, institutional investors, governance advisors and other key financial stakeholders. During Rob’s tenure, Roper’s market capitalization grew from $12 billion to over $45 billion.
Prior to Roper, Rob worked in investment banking at VRA Partners and Morgan Keegan, as a buy-side advisor at Devon Value Advisers and as a Capital Markets Consultant at Deloitte & Touche.
Crisci’s experience leading highly-engaged teams and long history of delivering strong financial performance has been recognized by Institutional Investor, who named him to its All-American Executive team in 2019 for the Multi-Industry CFO category.
“On behalf of Lineage’s management team and Board of Directors, we could not be more excited to have Rob join us as our CFO," said Lehmkuhl. "Rob is a proven public company financial leader who brings extensive operational and strategic expertise and a deep knowledge of the industrials and technology sectors. He will be an invaluable addition to the Lineage leadership team as we continue into our next phase of growth and expansion."
“I am thoroughly impressed with the incredible global growth Lineage has achieved over the past 10 years and look forward to leading its world-class finance team at such a pivotal point in the company’s history,” said Crisci. “I am excited for the opportunity to partner with Greg, the executive team, and the Board to further advance Lineage’s position as the world's leading and most innovative temperature-controlled logistics company.”
About Lineage Logistics
Lineage Logistics is one of the leading temperature-controlled industrial REIT and logistics solutions providers worldwide. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity which spans 20 countries across North America, Europe, and Asia-Pacific. Lineage has industry-leading expertise in end-to-end logistical solutions, an unrivaled real estate network, and develops and deploys innovative technology. This helps increase distribution efficiency, advance sustainability, minimize supply chain waste, and most importantly, as a Visionary Partner of Feeding America, helps feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was listed as No. 3 in the 2022 CNBC Disruptor 50 list, named a Deloitte US Best Managed Company in 2022, the No. 1 Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change the World list in 2020. (www.lineagelogistics.com)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230504005022/en/
Contact information
Lineage Logistics
Christina Wiese
734-608-1855
cwiese@lineagelogistics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fastly Joins DIMPACT to Collaborate on Digital Sustainability8.7.2026 15:00:00 EEST | Press release
Fastly, Inc. (NASDAQ: FSLY), a leading global edge cloud platform, today announced it has become a participant of DIMPACT, the coalition of leading organizations working to align industry changemakers and policymakers around meaningful, science-based solutions that reduce the environmental impacts of serving digital media products. As the first edge cloud platform provider to join the coalition, Fastly brings critical, real-world edge network data and infrastructure expertise and a transparent approach to emissions calculation and reporting to help major media, streaming, and publishing companies understand and optimize their digital carbon footprints. “We’re thrilled to welcome Fastly to the DIMPACT initiative. Their participation strengthens DIMPACT's ability to advance a more accurate, data-driven approach to measuring and reducing digital emissions,” said Jason Bell, Director at SLR Consulting and Executive Sponsor of DIMPACT. “Accurately calculating digital emissions requires a de
PubNub Introduces Blocks.ai: The Control Plane and Network Layer For AI Agents8.7.2026 15:00:00 EEST | Press release
PubNub introduces Blocks.ai today, a global network to connect and control agents across all agent frameworks, providers, and APIs. Blocks.ai lets developers reach their existing AI agents regardless of where they are hosted. Blocks Network supports all AI agent use cases without opening inbound ports, setting up tunnels, changing DNS, or modifying firewall rules. For more than a decade, PubNub has been the infrastructure and platform for real-time connectivity supporting billions of devices, now, PubNub delivers Blocks Network connecting the Internet of Agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708521206/en/ AI agents have become increasingly critical to businesses who want control over their models, code, and data. But once those agents are running locally or behind a firewall, making them reachable from custom frontends can require brittle infrastructure work. This is a key reason why McKinsey estimates th
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development8.7.2026 15:00:00 EEST | Press release
STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) today announced a partnership to expand access to high-quality human induced pluripotent stem cell (iPSC) starting materials, giving cell therapy developers worldwide a faster, lower-risk path from research to the clinic. Under the agreement, STEMCELL will manufacture and distribute research-use-only (RUO) iPSC lines derived directly from LineaBio's Good Manufacturing Practices (GMP) iPSC lines, and will offer the matched GMP lines to developers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708212795/en/ Partnership pairs GMP-manufactured iPSC lines with matched RUO equivalents, giving developers well-characterized, donor-eligible starting materials from early research through clinical development. Supporting comparability data for the RUO and GMP lines to be presented at the 2026 ISSCR Annual Meeting in Montréal, Canada
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 15:00:00 EEST | Press release
The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer of its kind, combining quantum error correction with NISQ qubits. The system will be delivered in 2027, followed by a series of upgrades delivered in multiple phases with an increasing number of logical qubits. The IQM Halocene H4 and the upgraded systems will enable LUMI consortium users, for the first time, to develop and implement Quantum Error Correction (QEC) concepts on a world-leadi
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden, the lack of targeted treatment makes the disease hard to control,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “This Breakthrough Therapy designation demonstrates that enpatoran has the potential to redefine how we approach lupus, by addressing the visible burden of rash, while potentially driving benefit beyond the skin. We look forward to working with the FDA to potentially bring this much-needed option to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom